Gap timing
Year 2
When data quality starts to drift
Root cause
Infrastructure
Under-resourced after approval
Fix
Continuity
Planned from day one
Post-Approval RWE Model
Enroll · Sustain · Monitor · Report
Pre-approval trials run with urgency. Regulatory timelines, milestone payments, and organizational attention all concentrate resources and scrutiny on execution quality. Sites are engaged. Patient support is funded. Compliance monitoring is active.
Post-approval RWE studies often start with similar intentions and quickly diverge. The urgency is gone. The device or drug is already approved. Internal teams redirect their attention to the next pre-approval program. Sites become less attentive as the novelty of the study fades. The operational infrastructure that was fully funded for the pivotal trial gets quietly reduced for the post-approval follow-up.
The result appears in year-two data: missing assessments, lost-to-follow-up rates that were not anticipated in the protocol, data completeness rates that cannot support the planned analyses, and a scramble to document why the gaps occurred rather than evidence of active follow-up attempts.
See also: Post-Market Studies · Post-Market Compliance
These are the specific failure modes that characterize post-approval RWE studies when the operational infrastructure was not built for the full study arc.
Patients who stop responding to contact attempts are often not flagged as lost-to-follow-up until the next scheduled assessment window — months later. Without between-visit engagement and early detection of communication breakdown, disengagement becomes loss before the team knows there is a problem.
Assessment completion rates that were strong in year one decline gradually in year two and beyond. This is not a sudden failure — it is a slow erosion that is easy to miss in aggregate metrics until it has already compromised the endpoint's analytic validity.
Staff turnover at sites — coordinators leaving, investigators moving to different roles — creates relationship continuity breaks that are rarely managed actively. New site staff may not have the same investment in a long-running post-approval study.
Patient addresses, phone numbers, and email addresses change. Studies that captured this information at enrollment and never verified it lose the ability to reach patients as time passes. Contact record maintenance is operational infrastructure that is routinely de-prioritized.
Post-approval studies using connected devices or eDiary platforms face technology lifecycle risk. App updates break compatibility, device batteries degrade, and platforms may sunset features or require patient re-onboarding without a proactive management plan.
Post-approval studies must demonstrate active follow-up effort when data is missing. Studies without systematic documentation of contact attempts, reasons for non-completion, and recovery steps taken cannot satisfy regulatory documentation requirements — regardless of how much effort was actually made.
Real-world evidence is increasingly accepted by regulators for certain purposes, including label extensions, pediatric studies, and rare disease applications. The data quality requirements are similar to those for clinical trials — incomplete or poorly documented RWE is unlikely to support a regulatory submission.
Post-approval studies need consistent funding across the full study arc, not a front-loaded model that reduces resources as the study matures. Patient support, compliance monitoring, and site engagement need to be sustained across all follow-up years — with explicit planning for years three, four, and five, not just year one.
Platforms with a track record of long-term stability, low patient burden, and active patient support are best suited for post-approval programs. Studies that used complex technology in pre-approval phases often need to simplify for post-approval follow-up to maintain participation rates over multi-year periods.
Delve provides the patient engagement, compliance monitoring, and data continuity infrastructure that post-approval programs need to sustain evidence quality across multi-year follow-up periods.
Talk to Our Post-Market Team